Yelekçi, KemalMalcomson, ThomasYelekçi, KemalBorrello, Maria TeresaGanesan, A.Semina, ElenaDe Kimpe, NorbertMangelinckx, SvenRamsay, Rona R.2019-06-272019-06-272015301742-464X1742-46581742-464X1742-4658https://hdl.handle.net/20.500.12469/578https://doi.org/10.1111/febs.13260Cyclopropylamines inhibitors of monoamine oxidases (MAO) and lysine-specific demethylase (LSD1) provide a useful structural scaffold for the design of mechanism-based inhibitors for treatment of depression and cancer. For new compounds with the less common cis relationship and with an alkoxy substituent at the 2-position of the cyclopropyl ring the apparent affinity determined from docking experiments revealed little difference between the enantiomers. Using the racemate kinetic parameters for the reversible and irreversible inhibition of MAO were determined. No inhibition of LSD1 was observed. For reversible inhibition most compounds gave high IC50 values with MAO A but sub-micromolar values with MAO B. After pre-incubation of the cyclopropylamine with the enzyme the inhibition was irreversible for both MAOA and MAOB and the activity was not restored by dilution. Spectral changes during inactivation of MAOA included bleaching at 456nm and an increased absorbance at 400nm consistent with flavin modification. These derivatives are MAOB-selective irreversible inhibitors that do not show inhibition of LSD1. The best inhibitor was cis-N-benzyl-2-methoxycyclopropylamine with an IC50 of 5nm for MAOB and 170nm for MAOA after 30min pre-incubation. This cis-cyclopropylamine is over 20-fold more effective than tranylcypromine so may be studied as a lead for selective inhibitors of MAOB that do not inhibit LSD1.eninfo:eu-repo/semantics/openAccessCyclopropylamineDockingFlavin adductMechanism-based inhibitorMonoamine oxidaseArticle3190319816282WOS:00036001670001510.1111/febs.132602-s2.0-84939250541Q1Q125755053